a few people working at a table

Press Releases

Ladenburg Acts as Exclusive Placement Agent in $6.5 Million Financing for Biodexa Pharmaceuticals

Ladenburg also acts as Exclusive Advisor for In-License of Phase 3 Ready Asset, eRapa for Familial Adenomatous...

Ladenburg Acts as Exclusive Placement Agent for Intelligent Bio Solutions in their $10.1 Million Private Placement

Transaction Information Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company") announced the...

Ladenburg Acts as Exclusive Placement Agent in the $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules for Palisade Bio, Inc.

Transaction Information Palisade Bio, Inc. (Nasdaq: PALI) announced that it has closed its private placement with...

Ladenburg Acts as Exclusive Placement Agent in the $1.77 Million Warrant Exercise Transaction for Intelligent Bio Solutions Inc.

Transaction Information Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company") announced an...

Ladenburg Acts as Sole Book-Running Manager in $4.172 Million Underwritten Public Offering for Peraso, Inc.

Transaction Information Peraso Inc. (NASDAQ:PRSO) ("Peraso" or the "Company") announced the closing of its...

Ladenburg Thalmann Acts as Placement Agent for Immunic, Inc in a Private Placement of up to $240 Million

Transaction Information Immunic, Inc. (Nasdaq: IMUX) announced it has entered into a securities purchase agreement...

Ladenburg Acts as Exclusive Placement Agent in the $2.5 Million Warrant Exercise Transaction for Palisade Bio, Inc.

Transaction Information Palisade Bio, Inc. (Nasdaq: PALI) ("Palisade" or the "Company") announced an agreement...

Ladenburg Thalmann Acts as Sole Book-Running Manager in $6 Million Underwritten Public Offering for Biodexa Pharmaceuticals PLC

Transaction Information Biodexa Pharmaceuticals PLC (Nasdaq: BDRX) announced the closing of an underwritten public...

Ladenburg Thalmann Acts as Exclusive Financial Advisor to Aileron Therapeutics, Inc. (ALRN) in its Acquisition of Lung Therapeutics, Inc.

On October 31, 2023, Aileron Therapeutics, Inc. (NASDAQ: ALRN) announced the completion of its acquisition of Lung...